Group 1 - The company, Encounter Noodle (02408), announced a share buyback plan, intending to repurchase approximately 109,000 shares at a cost of about HKD 635,700 [1]

长风药业(02652)发布公告，该公司于2026年2月12日斥资57.99万港元回购1.65万股股份，每股回购价格 为34.76-35.58港元。 ...

Group 1 - 康哲药业 has signed an exclusive distribution agreement with Teikoku Pharma USA, Inc. for the Lidoderm product, granting the company exclusive rights in mainland China for ten years starting from the first commercial sale [1] - Lidoderm is a lidocaine patch approved by the FDA in 1999 for treating postherpetic neuralgia (PHN), with clinical studies showing about 25% to 33% of patients experiencing at least 50% pain relief within 4 to 12 weeks [2] - The prevalence of PHN is significant, with estimates suggesting that approximately 4 million patients in China may be affected, particularly among older populations [3] Group 2 - Teikoku Pharma USA, Inc. is a subsidiary of Teikoku Seiyaku Co., Ltd., which has a long history in developing innovative products for pain management and other therapeutic areas [4] - The introduction of Lidoderm enhances 康哲药业's product portfolio and is expected to synergize with existing products, expanding market reach and driving growth [5] - The company aims to leverage new retail and multi-channel marketing strategies to create a comprehensive commercial ecosystem, enhancing both hospital and outpatient market penetration [5]

陈德耀先生(陈先生)因本集团内部工作安排，已辞任本公司执行董事一职，自2026年2月12日起生效。 陈先生于辞任本公司执行董事后，将继续留任本公司首席营运总监。 华营建筑(01582)发布公告，潘树杰先生(潘先生)因已届退休年龄，已辞任本公司执行董事，自2026年2 月12日起生效。潘先生于辞任本公司执行董事后，将继续留任本公司行政总裁。 董事会欣然宣布，金宏亮先生(金先生)获委任为非执行董事，自2026年2月12日起生效。 ...

贪玩(09890)发布公告，于2026年2月12日，该公司斥资56.98万港元回购2.94万股。 ...

百胜中国(09987)公布，2026年2月11日耗资约300万美元回购约5.28万股股份，耗资约771.19万港元回购 1.74万股股份。 ...

中国光大银行(06818)发布公告，公司已于2026年2月11日向2026年2月10日在中国证券登记结算有限责 任公司上海分公司登记在册的本公司第三期优先股股东足额支付优先股票面金额及2026年1月1日至2026 年2月10日持有期间的股息，共计人民币351.48亿元，赎回公司全部已发行的第三期优先股。 根据中登上海分公司提供的数据，第三期优先股已于2026年2月11日注销。公司第三期优先股的赎回及 摘牌已完成。 ...

Group 1 - The core point of the article is that HaiGe Communication (002465.SZ) announced that shareholder Mr. Yang Haizhou plans to reduce his holdings in the company by up to 4 million shares within three months, starting from 15 trading days after the announcement [1] Group 2 - The planned share reduction represents approximately 0.1624% of the company's total share capital, excluding shares held in the repurchase special account [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has announced its participation in the national organized procurement for drugs whose agreements have expired, with several of its products, including montmorillonite powder, being proposed for selection in this procurement process [1] Group 1: Procurement Results - The company has a total of 12 products proposed for selection in the recent procurement [1] - The expected sales revenue from these selected products for 2024 is 176.18 million yuan, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 2: Market Impact - Medical institutions will prioritize the use of the selected drugs from this procurement, ensuring the completion of the agreed procurement volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and promote the domestic market development of the company's products [1] - This development is expected to enhance the company's brand influence in the market [1]

德康农牧(02419)发布公告，于2026年2月12日，该公司斥资29.88万港元回购4200股。 ...